Table 4 Baseline characteristics and demographics for patients enrolled in phase 2 (n = 33)^a

Median age, years (range)

67.0 (47–83)

Male, n (%)

22 (66.7)

Median time from initial diagnosis, months (range)

31.8 (0.3–210.0)

Median prior systemic therapies, n (range)

1 (0–4)

Median time since last MF treatment^c, months (range)

1.68 (0.6-36.4)

 0

6 (18.2)

 1

19 (57.6)

 2

8 (24.2)

JAK2 mutation^d, n (%)

27 (81.8)

 Primary myelofibrosis

17 (51.5)

 Post-polycythemia vera myelofibrosis

12 (36.4)

 Post-essential thrombocythemia myelofibrosis

4 (12.1)

 High risk

1 (3.0)

 Intermediate risk

7 (21.2)

 Low risk

2 (6.1)

 Missing^e

23 (69.7)

 High risk

7 (21.2)

 Intermediate-2 risk

9 (27.3)

 Intermediate-1 risk

3 (9.1)

 Indeterminate^f

14 (42.4)

 Median^g, g/L (range)

90.0 (37–144)

 Grade 0–2, n (%)

27 (81.8)

 Grade 3, n (%)

6 (18.2)

   <10 g/L

20 (60.6)

   <8 g/L

6 (18.2)

 RBC-transfusion dependent^g, n (%)

6 (19.4)

 Median^g, ×10⁹/L (range)

126.0 (28–494)

 Grade 0–2, n (%)

29 (87.9)

 Grade 3, n (%)

4 (12.1)

   <100 × 10⁹/L

10 (42.4)

   <50 × 10⁹/L

4 (12.1)

 Platelet-transfusion dependent^g, n (%)

0

 Median^g, ×10⁹/L (range)

8.91 (1.5–38.2)

 Grade 0–2, n (%)

31 (93.9)

 Grade 3, n (%)

2 (6.1)

 Baseline leukocyte count >25 × 10⁹/L, n (%)

3 (9.1)